Literature DB >> 32310259

Comparison of Placebos and Propensity Score Adjustment in Multiple Sclerosis Nonrandomized Studies.

Alessio Signori1, Fabio Pellegrini2, Francesca Bovis1, Luca Carmisciano1, Carl de Moor3, Maria Pia Sormani1,4.   

Abstract

Mesh:

Substances:

Year:  2020        PMID: 32310259      PMCID: PMC7171579          DOI: 10.1001/jamaneurol.2020.0678

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN: 2168-6149            Impact factor:   18.302


× No keyword cloud information.
  6 in total

Review 1.  Treatment decisions in multiple sclerosis - insights from real-world observational studies.

Authors:  Maria Trojano; Mar Tintore; Xavier Montalban; Jan Hillert; Tomas Kalincik; Pietro Iaffaldano; Tim Spelman; Maria Pia Sormani; Helmut Butzkueven
Journal:  Nat Rev Neurol       Date:  2017-01-13       Impact factor: 42.937

2.  Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.

Authors:  Robert J Fox; David H Miller; J Theodore Phillips; Michael Hutchinson; Eva Havrdova; Mariko Kita; Minhua Yang; Kartik Raghupathi; Mark Novas; Marianne T Sweetser; Vissia Viglietta; Katherine T Dawson
Journal:  N Engl J Med       Date:  2012-09-20       Impact factor: 91.245

3.  Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.

Authors:  Ralf Gold; Ludwig Kappos; Douglas L Arnold; Amit Bar-Or; Gavin Giovannoni; Krzysztof Selmaj; Carlo Tornatore; Marianne T Sweetser; Minhua Yang; Sarah I Sheikh; Katherine T Dawson
Journal:  N Engl J Med       Date:  2012-09-20       Impact factor: 91.245

4.  Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study.

Authors:  Tomas Kalincik; J William L Brown; Neil Robertson; Mark Willis; Neil Scolding; Claire M Rice; Alastair Wilkins; Owen Pearson; Tjalf Ziemssen; Michael Hutchinson; Christopher McGuigan; Vilija Jokubaitis; Tim Spelman; Dana Horakova; Eva Havrdova; Maria Trojano; Guillermo Izquierdo; Alessandra Lugaresi; Alexandre Prat; Marc Girard; Pierre Duquette; Pierre Grammond; Raed Alroughani; Eugenio Pucci; Patrizia Sola; Raymond Hupperts; Jeannette Lechner-Scott; Murat Terzi; Vincent Van Pesch; Csilla Rozsa; François Grand'Maison; Cavit Boz; Franco Granella; Mark Slee; Daniele Spitaleri; Javier Olascoaga; Roberto Bergamaschi; Freek Verheul; Steve Vucic; Pamela McCombe; Suzanne Hodgkinson; Jose Luis Sanchez-Menoyo; Radek Ampapa; Magdolna Simo; Tunde Csepany; Cristina Ramo; Edgardo Cristiano; Michael Barnett; Helmut Butzkueven; Alasdair Coles
Journal:  Lancet Neurol       Date:  2017-02-11       Impact factor: 44.182

5.  Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis.

Authors:  J William L Brown; Alasdair Coles; Dana Horakova; Eva Havrdova; Guillermo Izquierdo; Alexandre Prat; Marc Girard; Pierre Duquette; Maria Trojano; Alessandra Lugaresi; Roberto Bergamaschi; Pierre Grammond; Raed Alroughani; Raymond Hupperts; Pamela McCombe; Vincent Van Pesch; Patrizia Sola; Diana Ferraro; Francois Grand'Maison; Murat Terzi; Jeannette Lechner-Scott; Schlomo Flechter; Mark Slee; Vahid Shaygannejad; Eugenio Pucci; Franco Granella; Vilija Jokubaitis; Mark Willis; Claire Rice; Neil Scolding; Alastair Wilkins; Owen R Pearson; Tjalf Ziemssen; Michael Hutchinson; Katharine Harding; Joanne Jones; Christopher McGuigan; Helmut Butzkueven; Tomas Kalincik; Neil Robertson
Journal:  JAMA       Date:  2019-01-15       Impact factor: 56.272

6.  A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.

Authors:  Chris H Polman; Paul W O'Connor; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; David H Miller; J Theodore Phillips; Fred D Lublin; Gavin Giovannoni; Andrzej Wajgt; Martin Toal; Frances Lynn; Michael A Panzara; Alfred W Sandrock
Journal:  N Engl J Med       Date:  2006-03-02       Impact factor: 91.245

  6 in total
  1 in total

1.  Recommendations for the use of propensity score methods in multiple sclerosis research.

Authors:  Gabrielle Simoneau; Fabio Pellegrini; Thomas Pa Debray; Julie Rouette; Johanna Muñoz; Robert W Platt; John Petkau; Justin Bohn; Changyu Shen; Carl de Moor; Mohammad Ehsanul Karim
Journal:  Mult Scler       Date:  2022-04-06       Impact factor: 5.855

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.